Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
16.03
Dollar change
-0.26
Percentage change
-1.60
%
IndexRUT P/E- EPS (ttm)- Insider Own30.46% Shs Outstand14.48M Perf Week4.29%
Market Cap232.11M Forward P/E- EPS next Y- Insider Trans0.46% Shs Float10.07M Perf Month4.09%
Income- PEG- EPS next Q-3.38 Inst Own63.77% Short Float8.89% Perf Quarter12.65%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio9.23 Perf Half Y-
Book/sh15.15 P/B1.06 EPS next Y- ROA- Short Interest0.90M Perf Year-
Cash/sh15.67 P/C1.02 EPS next 5Y- ROE- 52W Range10.80 - 18.95 Perf YTD15.16%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-15.41% Beta-
Dividend TTM- Quick Ratio6.20 Sales past 5Y-17.88% Gross Margin- 52W Low48.43% ATR (14)0.61
Dividend Ex-Date- Current Ratio6.20 EPS Y/Y TTM- Oper. Margin- RSI (14)54.77 Volatility2.98% 3.62%
Employees- Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price15.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q- Payout- Rel Volume0.36 Prev Close16.29
Sales Surprise- EPS Surprise3585.56% Sales Q/Q- EarningsAug 13 AMC Avg Volume97.04K Price16.03
SMA201.91% SMA503.33% SMA2008.89% Trades Volume35,220 Change-1.60%
Date Action Analyst Rating Change Price Target Change
Jul-23-24Initiated JMP Securities Mkt Perform
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded on January 8, 2024 and is headquartered in La Jolla, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lappe MarkChief Executive OfficerSep 12 '24Buy15.0526,963405,793692,511Sep 16 05:12 PM
Lappe MarkChief Executive OfficerSep 16 '24Buy17.1313,037223,324705,548Sep 16 05:12 PM
Vuori Kristiina MDDirectorSep 11 '24Buy15.076,45797,30713,776Sep 12 05:14 PM
Vuori Kristiina MDDirectorSep 10 '24Buy15.001792,6857,319Sep 12 05:14 PM
Lappe MarkChief Executive OfficerSep 06 '24Buy15.2926,000397,540647,548Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 09 '24Buy15.219,500144,495657,048Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 10 '24Buy15.198,500129,115665,548Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 03 '24Buy15.8120,000316,263165,000Sep 03 05:31 PM
Lappe MarkChief Executive OfficerAug 29 '24Buy14.0310,000140,300135,000Sep 03 05:31 PM
Lappe MarkChief Executive OfficerAug 30 '24Buy14.0210,000140,200145,000Sep 03 05:31 PM
Vuori Kristiina MDDirectorAug 29 '24Buy14.007,14099,9607,140Sep 03 04:27 PM
MANHARD KIMBERLYDirectorAug 28 '24Buy13.9810,000139,80010,000Aug 30 04:16 PM
FORSYTH DOUGLASDirectorAug 23 '24Buy14.0759,812841,555224,564Aug 26 04:26 PM
FORSYTH DOUGLASDirectorAug 22 '24Buy12.8915,188195,773164,752Aug 26 04:26 PM
Lappe MarkChief Executive OfficerAug 20 '24Buy12.9727,055350,90341,920Aug 22 04:29 PM
Lappe MarkChief Executive OfficerAug 21 '24Buy12.9312,945167,37954,865Aug 22 04:29 PM
Kayyem Jon FaizDirectorJun 05 '24Buy17.3257,549997,0241,150,410Jun 07 06:05 PM
Eckelman Brendan P.Chief Scientific OfficerMay 28 '24Sale34.30300,00010,290,0001,735,553May 30 06:21 PM